Novartis's cholesterol drug trial setback
Novartis suffers a major trial setback for its cholesterol drug, rattling investors and casting doubt on a multibillion-dollar market race.
2 stories10 sourcesUpdated Sep 8, 2026
Key developments
Novartis's stock sinks after its latest cholesterol drug trial setback.
5 sources on this →The cholesterol drug setback casts doubt over a multibillion-dollar race among drugmakers.
5 sources on this →
Coverage across the spectrum
Sponsored
Claim check
What each side asserts, disputes — or leaves out entirely.
Stories in this storyline
Comments
Ask Genius by OpenServe:
Free account · your comment posts right after signup
Sponsored